B+
Bull case
25%
Probability
Target price
$11.00
+43.8% vs current
DRIO
DarioHealthCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$7.50
-2.0% vs current
B-
Bear case
30%
Probability
Target price
$4.00
-47.7% vs current
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+42.8
Score
AI commentary
Sentiment is mildly constructive but clearly lower-conviction than a typical growth-medtech long. The March 2026 update improved the operating-loss and pipeline narrative, yet the 10-K still reads as a cash-runway and execution story first, not a proven breakout. The April 13, 2026 8-K announcing John R. Palumbo's board appointment is directionally positive for governance/commercial credibility, but it does not by itself change the core thesis [#8-K-2026-04-13].
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15eventNext earnings update must confirm post-Twill revenue stabilizationHigh impact
March 19, 2026 results showed Q4 revenue of $5.2M versus $5.0M in Q3, but management also said the year-over-year decline reflected a large national health plan client from the Twill acquisition that was not renewed at the start of 2025 [#PR-2026-03-19]. The next quarterly release is the first clean checkpoint on whether sequential growth is durable once that legacy drag is lapped.
2026-05-15catalystQ1 2026 filing tests liquidity and covenant headroomHigh impact
The key near-term issue is whether Dario can keep shrinking cash burn without tripping lender constraints. The 10-K said cash and short-term deposits were about $26.0M at December 31, 2025, while the amended Callodine facility requires at least $10.0M of consolidated unencumbered liquid assets and leaves part of remaining availability discretionary [#10-K-2026-03-19]. A clean Q1 update would support runway; a weak filing could quickly revive dilution/default concerns.
2026-12-31catalyst2026 conversion of contracted ARR and pipeline into recognized revenueHigh impact
Management said 2025 produced 85 new contracts, $12.9M of contracted and late-stage ARR expected to contribute in 2026 and 2027, and a commercial pipeline of $122M across roughly 230 mostly B2B2C opportunities, with more than 70% multi-condition [#PR-2026-03-19]. If those wins convert on schedule, the setup supports operating leverage; if conversion slips, the equity likely stays trapped in monitoring mode.
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology